Comprehensive Therapy

, Volume 28, Issue 2, pp 109–122 | Cite as

Treatment of osteoporosis: Current status and recent advances

  • Daphne J. Theodorou
  • Stavroula J. Theodorou
  • David J. Sartoris
Original Article


With the advent of new treatment choices, osteoporosis should no longer be considered an inevitable part of aging but rather a disease that can be treated. This article provides an overview of recent advances in treatment of osteoporosis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heaney R. Calcium in the prevention and treatment of osteoporosis. J Intern Med. 1992;231:169–180.PubMedGoogle Scholar
  2. 2.
    Heaney R. Bone mass nutrition and, other lifestyle factors. Am J Med. 1993;95(Suppl 5A):29S-33S.PubMedCrossRefGoogle Scholar
  3. 3.
    Levenson D, Bockman R. A review of calcium preparations. Nutr Rev. 1994;52:221–232.PubMedCrossRefGoogle Scholar
  4. 4.
    Matkovic V. Calcium and peak bone mass. J Intern Med. 1992;31:151–160.Google Scholar
  5. 5.
    Heaney R, Gallagher J, Johnston C, Neer R, Parfitt AM, Whedon GD. Calcium nutrition and bone health in the elderly. Am J Clin Nutr. 1982;36:986–1013.PubMedGoogle Scholar
  6. 6.
    Dawson-Hughes B, Dallal G, Krall E, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med. 1990;323:878–883.PubMedCrossRefGoogle Scholar
  7. 7.
    Prince R, Smith M, Dick I, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation and hormone-replacement therapy. N Engl J Med. 1991;325:1189–1195.PubMedCrossRefGoogle Scholar
  8. 8.
    Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind controlled study. N Engl J Med. 1987;316:173–177.PubMedCrossRefGoogle Scholar
  9. 9.
    Lane JM, Cornell CN, Healey JH. Osteoporosis: the structural and reparative consequences for the skeleton. Instr Course Lect. 1987;36:71–83.PubMedGoogle Scholar
  10. 10.
    Lane JM, Cornell CN, Healey JH. Orthopaedic consequences of osteoporosis. In: Riggs B, Melton L, eds. Osteoporosis. Etiology, Diagnosis and Management. New York; Raven Press: 1988:433–455.Google Scholar
  11. 11.
    Mohler D, Lane JM, Cole B, Weinerman S Skeletal failure in osteoporosis. In: Lane JM, Healey JH, eds. Diagnosis and Management of Pathologic Fractures. New York; Raven Press: 1993;13–36.Google Scholar
  12. 12.
    NIH Conference: Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA. 1994; 272:1942–1948.CrossRefGoogle Scholar
  13. 13.
    Pak C, Breslow N, Harvey J. Nutrition and metabolic bone disease. In: Scarpelli D, Migaki G, eds. Nutritional Diseases: Research Directions in Comparative Pathobiology. New York; Liss: 1986:215.Google Scholar
  14. 14.
    Riggs BL, Wahner HW, Melton LJ Jr, Richelson LS, Judd HL, O'Fallon WM. Dietary calcium intake and rates of bone loss in women. J Clin Invest. 1987;80:979–982.PubMedGoogle Scholar
  15. 15.
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637–1642.PubMedCrossRefGoogle Scholar
  16. 16.
    Nicar M, Pak C. Calcium bioavailability from calcium carbonate and calcium citrate. J Clin Endocrinol Metab. 1985;61: 391–393.PubMedGoogle Scholar
  17. 17.
    Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: Relationship between serum 1,25-dihydroxy vitamin D and intestinal vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab. 1992;75:176–182.PubMedCrossRefGoogle Scholar
  18. 18.
    Barger-Lux MJ, Heaney RP, Lanspa SJ, Healy JC, DeLuca HF. An investigation of sources of variation in calcium absorption efficacy. J Clin Endocrinol Metab. 1995;80:406–411.PubMedCrossRefGoogle Scholar
  19. 19.
    Bauwens S. Osteomalacia and osteoporosis. In: DiPiro J, Talbert R, Hayes P, et al, eds., Pharmacotherapy: A Pathophysiologic Approach. 2nd Ed. New York; Elsevier Science Publishing Co, Inc: 1992;1293–1312.Google Scholar
  20. 20.
    Levine BS, Rodman JS, Weinerman S, Bockman RS, Lane JM, Chapman DS. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: Implications for prevention of osteoporosis. Am J Clin Nutr. 1994;60:592–596.PubMedGoogle Scholar
  21. 21.
    Sheikh M, Fordtran J. Calcium bioavailability from two calcium carbonate preparations. N Engl J Med. 1990;323:921PubMedGoogle Scholar
  22. 22.
    Rosen C, Hunter S, Verereault D, et al. A randomized placebo-controlled trial of calcium carbonate vs dairy supplementation in elderly N England women [Abstract]. J Bone Miner Res. 1996;11:S133.Google Scholar
  23. 23.
    Corazza GR, Benati G, DiSario A, et al. Lactose intolerance and bone mass in postmenopausal Italian women. Br J Nutr. 1995;73:479–487.PubMedCrossRefGoogle Scholar
  24. 24.
    Walters J. Bone mineral ensity in coeliac disease. Gut. 1994;35:150–151.PubMedGoogle Scholar
  25. 25.
    Whiting S. Safety of some calcium supplements questioned. Nutr Rev. 1994;52:95–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Khaw K, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr. 1994;59:1040–1044.PubMedGoogle Scholar
  27. 27.
    Menczel J, Foldes J, Steinberg R, et al. Alfacalcidol (alpha D3) and calcium in osteoporosis. Clin Orthop. 1994;300:241–247.PubMedGoogle Scholar
  28. 28.
    Orimo H, Shiraki M, Hayashi NT, Nakamura T. Reduced occurence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone Miner. 1987;3:47–52.PubMedGoogle Scholar
  29. 29.
    Tilyard M, Spears G, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992;326:357–362.PubMedCrossRefGoogle Scholar
  30. 30.
    Komar L, Nieves J, Cosman E, Rubin A, Shen V, Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc. 1993;41:1057–1064.PubMedGoogle Scholar
  31. 31.
    Lamberg-Allardt C, Karkkainen M, Seppanen R, Bistrom H. Low serum 25-hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. Am J Clin Nutr. 1993;58:684–689.PubMedGoogle Scholar
  32. 32.
    Need A, Morris H, Horowitz M, Nordin C. Effects of skin thickness, age, body fat, and sunlight on serum 25 hydroxy vitamin D. Am J Clin Nutr. 1993;58:882–885.PubMedGoogle Scholar
  33. 33.
    Shiraki M, Orimo H, Ito H, et al. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1OHD3) and 2,24 dihydroxycholecalciferol (1,24 (OH)2D3). Endocrinol Jpn. 1985;32:305–315.PubMedGoogle Scholar
  34. 34.
    Lobo R. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol. 1995;173:982–989.PubMedCrossRefGoogle Scholar
  35. 35.
    Girasole G, Jilka RL, Passeri G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883–891.PubMedCrossRefGoogle Scholar
  36. 36.
    Jilka R, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin 6. Science. 1992;257:88–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Nat Acad Sci USA. 1991;88:6613–6617.PubMedCrossRefGoogle Scholar
  38. 38.
    Pacifici R, Rifas L, McCracken R, et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Nat Acad Sci USA. 1989;86: 2398–2402.PubMedCrossRefGoogle Scholar
  39. 39.
    Corson S. A practical guide to prescribing estrogen replacement therapy. Int J Fertil. 1995;40:229–247.Google Scholar
  40. 40.
    Ettinger B, Genant H, Cann C. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102:319–324.PubMedGoogle Scholar
  41. 41.
    Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. N Engl J Med. 1987;317:1169–1174.PubMedCrossRefGoogle Scholar
  42. 42.
    Lindsay R, Hart D, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2: 1151–1154.PubMedCrossRefGoogle Scholar
  43. 43.
    Danielsen C, Mosekilde L, Svenstrup B. Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue Int. 1993;52:26–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Ensrud K, Palermo L, Black D, et al. Hip bone loss increases with advancing age: longitudinal results from The Study of Osteoporotic Fractures [Abstract]. J Bone Miner Res. 1994;9 (Suppl 1):153.Google Scholar
  45. 45.
    Davis J, Ross P, Johnson N, Wasnich R. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone. 1995;17:369–373.PubMedCrossRefGoogle Scholar
  46. 46.
    Lees B, Pugh M, Siddle N, Stevenson JC. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos Int. 1995;5:344–348.PubMedCrossRefGoogle Scholar
  47. 47.
    Kohrt W, Birge S. Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist, and total body in late postmenopausal women. Osteoporos Int. 1995;5: 150–155.PubMedCrossRefGoogle Scholar
  48. 48.
    Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646–650.CrossRefGoogle Scholar
  49. 49.
    Cummings S, Rubin S, Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal oestrogen. Clin Orthop. 1990;252:163–166.PubMedGoogle Scholar
  50. 50.
    Christiansen C, Christensen M, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981;1: 459–461.PubMedCrossRefGoogle Scholar
  51. 51.
    Felson D, Zhang Y, Hannan M, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329: 1141–1146.PubMedCrossRefGoogle Scholar
  52. 52.
    Lindsay R, Hart D, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet. 1978;1:1325–1327.PubMedCrossRefGoogle Scholar
  53. 53.
    Tremollieres F, Pouilles J, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab. 1993;77:683–686.PubMedCrossRefGoogle Scholar
  54. 54.
    Hollenbach K, Barrett-Connor E, Edelstein S, Holbrook T. Cigarette smoking and bone mineral density in older men and women. Am J Public Health. 1993;83:1265–1270.PubMedGoogle Scholar
  55. 55.
    Barrett-Connor E. Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases. Am J Med. 1993;95:40S-43S.PubMedCrossRefGoogle Scholar
  56. 56.
    Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med. 1993;95:37S-39S.PubMedCrossRefGoogle Scholar
  57. 57.
    Johnston C, Melton L. Guidelines for osteoporosis prophylaxis. J Bone Miner Res. 1990;5:423–424.PubMedGoogle Scholar
  58. 58.
    Thompson W. Estrogen replacement therapy in practice: trends and issues. Am J Obstet Gynecol. 1995;173:990–993.PubMedCrossRefGoogle Scholar
  59. 59.
    Rozenberg S, Vandromme J, Kroll M, Praet JP, Peretz A, Ham H. Overview of the clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis. Int J Fertil. 1995;40:12–24.Google Scholar
  60. 60.
    Stanford J, Weiss N, Voigt L, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replace-ment therapy in relation to risk of breast cancer in middleaged women JAMA. 1995;274:137–142.PubMedCrossRefGoogle Scholar
  61. 61.
    Colditz G, Hankinson S, Hunter D, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–1593.PubMedCrossRefGoogle Scholar
  62. 62.
    Jick H, Derby L, Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981–983.PubMedCrossRefGoogle Scholar
  63. 63.
    Judd H, Meldrum D, Deftos L, Henderson B. Estrogen replacement therapy: indications and complications. Ann Intern Med. 1983;98:195–205.PubMedGoogle Scholar
  64. 64.
    Grady D, Rubin S, Petitti D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037.PubMedGoogle Scholar
  65. 65.
    Belchetz P. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062–1071.PubMedCrossRefGoogle Scholar
  66. 66.
    Grodstein F, Stampfer M, Colditz G, et al. Postmenopausal hormone therapy and mentality. N Engl J Med. 1997;336:1769–1775.PubMedCrossRefGoogle Scholar
  67. 67.
    Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis. Lancet. 1985;2:800–801.PubMedCrossRefGoogle Scholar
  68. 68.
    Henderson B, Paganini-Hill A, Ross R. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75–78.PubMedCrossRefGoogle Scholar
  69. 69.
    Session D, Kelly A, Jewelewicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril. 1993;59:277–284.PubMedGoogle Scholar
  70. 70.
    Nachtigall L. Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am J Obstet Gynecol. 1995;173:993–997.PubMedCrossRefGoogle Scholar
  71. 71.
    Gordon S. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol. 1995;173:998–1004.PubMedCrossRefGoogle Scholar
  72. 72.
    Stampfer M, Colditz G, Willett W, et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study. N Engl J Med. 1991; 325:756–762.PubMedCrossRefGoogle Scholar
  73. 73.
    Rozenburg S, Gevers R, Peretz A, Vandromme J, Robyn C, Ham H Decrease of bone mineral density during estrogen substitution therapy. Maturitas. 1993;17:205–210.CrossRefGoogle Scholar
  74. 74.
    Paganini-Hill A, Chao A, Rosa R, Henderson B. Exercise and other factors in the prevention of hip fracture: The Leisure World Study. Epidemiology. 1991;2:16–25.PubMedCrossRefGoogle Scholar
  75. 75.
    Lobo R, Pickar J, Wild R, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 1994;84:987–995.PubMedGoogle Scholar
  76. 76.
    The Postmenopausal Estrogen/Progestins Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273:199–208.CrossRefGoogle Scholar
  77. 77.
    Ettinger B, Grady D. The waning effect of postmenopausal estrogen therapy on osteoporosis [Editorial]. N Engl J Med. 1993;329:1192–1193.PubMedCrossRefGoogle Scholar
  78. 78.
    Riggs B, Melton L. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620–627.PubMedCrossRefGoogle Scholar
  79. 79.
    Lufkin E, Wahner H, O'Fallon W, et al., Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1–9.PubMedGoogle Scholar
  80. 80.
    Powels T, Hicklish T, Kanis J, et al. Effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1995;18:78–84.CrossRefGoogle Scholar
  81. 81.
    Davidson N. Tamoxifen-panacea or Pandora's box? N Engl J Med. 1992;326:885–886.PubMedCrossRefGoogle Scholar
  82. 82.
    Daniel T. Metabolic bone disease. In: John N, ed. Textbook of Primary Care Medicine. St Louis; CV Mosby Publisher: 1996: 557–563.Google Scholar
  83. 83.
    Harris S, Watts N, Jackson R, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year open therapy. Am J Med. 1993;95:557–567.PubMedCrossRefGoogle Scholar
  84. 84.
    Cantatore F, Acquista C, Piptone V. Evaluation of bone turnover and osteoclastic cytokins in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999;26:2318–2323.PubMedGoogle Scholar
  85. 85.
    Paterson A. The emerging role of biphosphonates in the prevention of bone metastases. Trends Endocrinol. Metab. 1999; 10:24–29.CrossRefPubMedGoogle Scholar
  86. 86.
    Fleish H. Biphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs. 1991;42:919–944.Google Scholar
  87. 87.
    Storm T, Steiniche T, Thamsborg G, Melson F. Changes in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993;8:199–208.PubMedGoogle Scholar
  88. 88.
    Boyce B, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984;1:821–824.PubMedCrossRefGoogle Scholar
  89. 89.
    Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP. Diphosphonates and inhibition of bone mineralization [Letter]. Lancet. 1982;2:607–608.PubMedCrossRefGoogle Scholar
  90. 90.
    Eyres KS, Marshall P, McCloskey E, Douglas DL, Kanis JA. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf. 1992;7:162–165.PubMedGoogle Scholar
  91. 91.
    Fleisch H. Biphosphonates: Mechanisms of action and clinical applications. In: Peck W, ed. Bone and Mineral Research Annual 1. Amsterdam: Excerpta Medica: 1983:319.Google Scholar
  92. 92.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;32:1265–1271.CrossRefGoogle Scholar
  93. 93.
    Chesnut CH 3rd, McClung MR, Ensrud CE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99:144–152.PubMedCrossRefGoogle Scholar
  94. 94.
    Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961–967.PubMedCrossRefGoogle Scholar
  95. 95.
    Balena R, Markatos A, Gentile M, et al. Bone turnover in the cortical bone of primates. Effects of the amino-biphosphonate alendronate [Abstract]. Calcif Tissue Int. 1993;52 (Suppl 1):S73.Google Scholar
  96. 96.
    Passeri M, Baroni M, Pedrazzoni M, Vesconi P. Protocols of treatment of chronic back pain in involutional osteoporosis. Bone Miner. 1993;22(Suppl):23–52.Google Scholar
  97. 97.
    Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437–1443.PubMedCrossRefGoogle Scholar
  98. 98.
    Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541.PubMedCrossRefGoogle Scholar
  99. 99.
    Lane J, Riley E, Wirganowizc P. Osteoporosis: Diagnosis and treatment. J Bone Joint Surg (Am). 1996;78:618–632.Google Scholar
  100. 100.
    Lane J, Riley e, Wirganowizc P. Letter on osteoporosis. J Bone Joint Surg (Am). 1997;79:634–635.Google Scholar
  101. 101.
    Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73–79.PubMedCrossRefGoogle Scholar
  102. 102.
    Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD. Diphosphonates in the treatment of myositis ossificans. Lancet. 1969;2:845.PubMedCrossRefGoogle Scholar
  103. 103.
    Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973;289:1379–1384.PubMedCrossRefGoogle Scholar
  104. 104.
    Siris ES, Canfield RE, Jacobs TP, Stoddart KE, Spector PJ. Clinical and biochemical effects of EHDP in Paget's disease of bone: Patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res. 1981;3:301–308.PubMedCrossRefGoogle Scholar
  105. 105.
    Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397–1402.PubMedGoogle Scholar
  106. 106.
    Cohen-Solal ME, Roux C, Valentin-Opran A, Dougados M, Amor B, De Vernejoul MC. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone. 1993;14:505–509.PubMedCrossRefGoogle Scholar
  107. 107.
    Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340:1049–1052.PubMedCrossRefGoogle Scholar
  108. 108.
    Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58:288–298.PubMedCrossRefGoogle Scholar
  109. 109.
    Anonymous. New drugs for osteoporosis. Med Lett Drugs Ther. 1996;38:1–4.Google Scholar
  110. 110.
    D'Arey P. Nutrient-drug interactions. Adverse Drug React Toxicol Rev. 1995;14:233–254.Google Scholar
  111. 111.
    Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after biphosphonate administration. Calcif Tissue Int. 1987;41:326–331.PubMedCrossRefGoogle Scholar
  112. 112.
    Gallacher SJ, Ralston SH, Patel U, Boyle IT. Side-effects of pamidronate [Letter]. Lancet. 1989;2:42–43.PubMedCrossRefGoogle Scholar
  113. 113.
    Fitton A, McTavish D. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1991;41:289–318.PubMedGoogle Scholar
  114. 114.
    Jodrell D, Iveson T, Smith I. Symptomatic hypocalcemia after treatment with high-dose aminohydroxypopylidene diphosphonate. Lancet. 1987;1:622.PubMedCrossRefGoogle Scholar
  115. 115.
    Mian M, Beghe F, Caprio A, Aloj R, Bertelli A. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol. Res. 1991;11:107–114.PubMedGoogle Scholar
  116. 116.
    Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833–1837.PubMedGoogle Scholar
  117. 117.
    Harris ST, Gertz BJ, Genant HK, et al. The effect of shortterm treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early post-menopausal women. J Clin Endocrinol Metab. 1992;76:1399–1406.CrossRefGoogle Scholar
  118. 118.
    Body J. Calcitonin: from the determination of circulating levels in various physiological and pathological conditions to the demonstration of lymphocyte receptors. Hormone Res. 1993;39:166–170.PubMedGoogle Scholar
  119. 119.
    Austin L, Heath H. Calcitonin: Physiology and pathophysiology. N Engl J Med. 1981;304:269–278.PubMedCrossRefGoogle Scholar
  120. 120.
    Azria M, Copp D, Zanelli J. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int. 1995;57:405–408.PubMedCrossRefGoogle Scholar
  121. 121.
    Reginster JY, Deroisy R, Lecart MP, et al. A double-blind placebo-controlled dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 1995;98:452–458.PubMedCrossRefGoogle Scholar
  122. 122.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ. 1992;305:556–561.PubMedGoogle Scholar
  123. 123.
    Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes. 1995;103:345–351.PubMedCrossRefGoogle Scholar
  124. 124.
    Oberman Z, Graf E, Hoerer E. ACTH, cortisol and endorphin produced by calcitonin administration [Abstract]. Isr J Med Sci. 1985;21:483.Google Scholar
  125. 125.
    Fiore CE, Castorina F, Malatino LS, Tamburino C. Antalgic activity of calcitonin: Effectiveness of the epidural and subarachnoid routes in man. Int J Clin Pharmacol Res. 1983;3:257–260.PubMedGoogle Scholar
  126. 126.
    Reginster J. Calcitonins: newer routes of delivery. Osteoporos Int. 1993;3(Suppl 2):3–7.CrossRefGoogle Scholar
  127. 127.
    Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, Nagant de Deuxchaisnes C. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int. 1994;1:71–73.CrossRefGoogle Scholar
  128. 128.
    Kanis J, McCloskey E. Effect of calcitonin on vertebral and other fractures. Q J Med. 1999;92:143–149.Google Scholar
  129. 129.
    Kleerekoper M, Avioli L. Evaluation and treatment of postmenopausal osteoporosis. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2Ed. New York; Raven Press: 1993: 223–229.Google Scholar
  130. 130.
    Levy F, Muff R, Dotti-Sigrist S, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J Clin Endocrinol Metab. 1988;67:541–545.PubMedGoogle Scholar
  131. 131.
    Grauer A, Reinel H, Ziegler R, Raue F. Neutralizing antibodies against calcitonin. Horm Metab Res. 1993;20:486–488.Google Scholar
  132. 132.
    Anonymous. Raloxifene for postmenopausal osteoporosis. Med Lett Drugs Ther. 1998;40:29–30.Google Scholar
  133. 133.
    Brzozowski AM, Pike AC, Dauder Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758.PubMedCrossRefGoogle Scholar
  134. 134.
    Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997;277:1508–1510.PubMedCrossRefGoogle Scholar
  135. 135.
    Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451.PubMedCrossRefGoogle Scholar
  136. 136.
    McClung M. Therapy for fracture prevention. JAMA. 1999;282:687–689.PubMedCrossRefGoogle Scholar
  137. 137.
    Johnell O, Scheele W, Lu Y, Lakshmanan M. Effects of raloxifene (RLX), alendronate (ALN) and RLX+ALN on bone mineral density (BMD) and biochemical markers on bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14 (Suppl 1):S157.Google Scholar
  138. 138.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647.PubMedCrossRefGoogle Scholar
  139. 139.
    The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199–208. [Erratum, JAMA. 1995;274:1676.]CrossRefGoogle Scholar
  140. 140.
    Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835–842.PubMedGoogle Scholar
  141. 141.
    Ringe J, Meunier P. What is the future for fluoride in the treatment of osteoporosis? Osteoporos Int. 1995;5:71–74.PubMedCrossRefGoogle Scholar
  142. 142.
    Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann. Intern Med. 1995; 123:401–408.PubMedGoogle Scholar
  143. 143.
    Riggs BL, Hodgson SP, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802–809.PubMedCrossRefGoogle Scholar
  144. 144.
    Riggs BL, O'Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res. 1994;96:265–275.Google Scholar
  145. 145.
    Gutteridge DH, Kent GN, Prince RL, et al. Fluoride treatment of osteoporosis: cyclical non-blinded or continuous blinded studies. Osteoporos Int. 1993; 3(Suppl 1):215–217.PubMedCrossRefGoogle Scholar
  146. 146.
    Farley S, Wergedal JE, Farley JR, et al. Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density. Osteoporos Int. 1992;2:213–218.PubMedCrossRefGoogle Scholar
  147. 147.
    Kleerekoper M. Fluoride: the verdict is in, but the controversy lingers [Editorial]. J Bone Miner Res. 1996;11:565–567.PubMedCrossRefGoogle Scholar
  148. 148.
    Sogaard C, Mosekilde Li, Richards A, Mosekilde L. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy assessed by biomechanical testing of iliac cress biopsies in osteoporotic patients. Bone. 1994;15:393–399.PubMedCrossRefGoogle Scholar
  149. 149.
    Kassem M, Mosekilde L, Eriksen E. 1,25 dihydroxyvitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res. 1993;8:1453–1458.PubMedGoogle Scholar
  150. 150.
    Alexandersen P, Riis B, Christiansen C. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab. 1999;84:3013–3020.PubMedCrossRefGoogle Scholar
  151. 151.
    Dure-Smith BA, Kraenzlin ME, Farley SM, Libanati CR, Schulz EE, Baylink DJ. Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action. Calcif Tissue Int. 1991;49(Suppl):S64-S67.PubMedCrossRefGoogle Scholar
  152. 152.
    Riggs B. Treatment of osteoporosis with sodium fluoride: an appraisal. In: Peck W, ed. Bone and Mineral Research, Annual 2: A Yearly Survey of Developments in the Field of Bone and Mineral. New York; Elsevier: 1984:366–393.Google Scholar
  153. 153.
    O'Duffy JD, Wahner HW, O'Fallon WM, et al. Mechanism of acute lower extremity pain syndrome in fluoride-treated osteoporotic patients. Am J Med. 1986;80:561–566.PubMedCrossRefGoogle Scholar
  154. 154.
    Schulz EE, Libanati CR, Farley SM, Kirk GA, Baylink DJ. Skeletal scintigraphic changes in osteoporosis treated with sodium fluoride: concise communication. J Nucl Med. 1984;25:651–655.PubMedGoogle Scholar
  155. 155.
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14:690–709.PubMedCrossRefGoogle Scholar
  156. 156.
    Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and estrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf). 1992;37:282–289.Google Scholar
  157. 157.
    Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. Br Med J. 1980;280:1340–1344.PubMedCrossRefGoogle Scholar
  158. 158.
    Neer M, Slovik DM, Daly M, Potts T Jr, Nussbaum SR. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int. 1993; 3(Suppl 1):204–205.PubMedCrossRefGoogle Scholar
  159. 159.
    Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–555.PubMedCrossRefGoogle Scholar
  160. 160.
    Sakhaee K, Nicar MJ, Glass K, Pak CY. Postmenopausal osteoporosis as a manifestation of renal hypercalciuria with secondary hyperparathyroidism. J Clin Endocrinol Metab. 1985;61:368–373.PubMedGoogle Scholar
  161. 161.
    Middler S, Pak CY, Murad F, Bartter FC. Thiazide diuretics and calcium metabolism. Metabolism. 1973;22:139–146.PubMedCrossRefGoogle Scholar
  162. 162.
    Transbol I, Christensen MS, Jensen GF, Christiansen C, McNair P. Thiazide for the postponement of postmenopausal bone loss. Metabolism. 1982;31:383–386.PubMedCrossRefGoogle Scholar
  163. 163.
    Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;304:344–347.CrossRefGoogle Scholar
  164. 164.
    Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med. 1993;118:666–673.PubMedGoogle Scholar
  165. 165.
    Jone G, Nguyen T, Sambrook P, Eisman J. Thiazide diuretics and fractures: can metaanalysis help? J Bone Miner Res. 1995;10:106–111.Google Scholar
  166. 166.
    LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990;322:286–290.PubMedCrossRefGoogle Scholar
  167. 167.
    Ray W, Downey W, Griffin M, Melton L. Long-term use of thiazide diuretics and risk of hip fracture. Lancet. 1989;1:687–690.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • Daphne J. Theodorou
    • 1
  • Stavroula J. Theodorou
    • 1
  • David J. Sartoris
    • 2
  1. 1.Department of Radiology University of CaliforniaSan Diego Veterans Affairs Medical CenterSan Diego
  2. 2.Department of Radiology University of CaliforniaSan Diego Thornton HospitalSan Diego

Personalised recommendations